A recent study of Aurora A kinase inhibitor MLN8054, MEK inhibitor trametinib, and BRAF inhibitor dabrafenib evaluated various combinations of these drugs in BRAF mutant melanoma cell lines (Caputo et al., 2014). Here, MAP2K7 is linked to melanoma.